Non-Fucosylated Anti-Human HER2 (TrasGEX) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-1838ZP) Datasheet

Target
HER2
Isotype
Humanized IgG1
Description
The ADCC-enhanced antibody is a glycosylation-modified therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of fucosylation level. By reducing or removing the fucose of the Fc region, we obtained the ADCC-enhanced antibody, which showed increased binding affinity to the FcyR receptor on immune effector cells in an in vitro ADCC assay compared to its patent fucosylated antibody.

More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Solid Tumors
Classification
Therapeutic antibody; biobetter
Status
Phase 1 (Completed)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ERBB2
Full Name
erb-b2 receptor tyrosine kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Gene ID
UniProt ID
Trade name
TrasGEX
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Species Reactivity
Human
Indication
Solid Tumors
Synonyms
GT-MAB7.3-GEX; Glycooptimized Trastuzumab-GEX

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK